CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Purpose: Previous studies in patients with non-Hodgkin's lymphoma (NHL) and other malignancies have suggested that the presence of host infiltrates in the tumors of these patients may predict a better out-come. This study was undertaken to determine the prognostic importrance of the presence of T cells in the biopsy specimens of patients with B-cell NHL. Patients and Methods: Seventy-two patients with diffuse large B-cell NHL were prospectively evaluated at a single institution between 1987 and 1994. The percentage of CD3+, CD3+/HLA-DR+, CD4+, CD8+, and natural killer cells was determined by flow cytometry in the pretreatment diagnostic biopsy specimen and correlated with patient outcome. Results: An increase in the percentage CD4+ T cells in the pretreatment tumor biopsies significantly correlated with patient outcome. The percent of CD4+ T cells was also highly correlated with CD3+/HLA-DR+, CD45RO+, and low L-selectin (CD62L) expression, indicating that the CD4+ T, cells are activated memory T-helper cells. Those patients with increased numbers of CD4+ T cells, compared with other patients, had a significantly longer 5-year failure-free survival (72% v 43%, respectively; P = .04), as well as a significantly longer 5-year overall survival (65% v 38%, respectively; P = .05). When evaluated in a multivariate model, the International Prognostic Index and more than 20% infiltrating CD4+ T cells in the pretreatment biopsy were significant independent predictors of relapse-free and overall survival. Conclusion: The presence of increased numbers of activated CD4+ cells in the area of B-cell diffuse large-cell NHL predicts a better prognosis. This finding provides a strong rationale for the investigation of cellular immunotherapy in B-cell NHL.

Original languageEnglish (US)
Pages (from-to)720-726
Number of pages7
JournalJournal of Clinical Oncology
Volume19
Issue number3
StatePublished - Feb 1 2001

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
T-Lymphocytes
Biopsy
HLA-DR Antigens
Survival
L-Selectin
Neoplasms
Helper-Inducer T-Lymphocytes
Natural Killer Cells
Immunotherapy
Flow Cytometry
B-Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{94254f4571734c7fadc8392e8fde2e30,
title = "CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome",
abstract = "Purpose: Previous studies in patients with non-Hodgkin's lymphoma (NHL) and other malignancies have suggested that the presence of host infiltrates in the tumors of these patients may predict a better out-come. This study was undertaken to determine the prognostic importrance of the presence of T cells in the biopsy specimens of patients with B-cell NHL. Patients and Methods: Seventy-two patients with diffuse large B-cell NHL were prospectively evaluated at a single institution between 1987 and 1994. The percentage of CD3+, CD3+/HLA-DR+, CD4+, CD8+, and natural killer cells was determined by flow cytometry in the pretreatment diagnostic biopsy specimen and correlated with patient outcome. Results: An increase in the percentage CD4+ T cells in the pretreatment tumor biopsies significantly correlated with patient outcome. The percent of CD4+ T cells was also highly correlated with CD3+/HLA-DR+, CD45RO+, and low L-selectin (CD62L) expression, indicating that the CD4+ T, cells are activated memory T-helper cells. Those patients with increased numbers of CD4+ T cells, compared with other patients, had a significantly longer 5-year failure-free survival (72{\%} v 43{\%}, respectively; P = .04), as well as a significantly longer 5-year overall survival (65{\%} v 38{\%}, respectively; P = .05). When evaluated in a multivariate model, the International Prognostic Index and more than 20{\%} infiltrating CD4+ T cells in the pretreatment biopsy were significant independent predictors of relapse-free and overall survival. Conclusion: The presence of increased numbers of activated CD4+ cells in the area of B-cell diffuse large-cell NHL predicts a better prognosis. This finding provides a strong rationale for the investigation of cellular immunotherapy in B-cell NHL.",
author = "Ansell, {Stephen Maxted} and M. Stenson and Habermann, {Thomas Matthew} and Jelinek, {Diane F} and Witzig, {Thomas Elmer}",
year = "2001",
month = "2",
day = "1",
language = "English (US)",
volume = "19",
pages = "720--726",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome

AU - Ansell, Stephen Maxted

AU - Stenson, M.

AU - Habermann, Thomas Matthew

AU - Jelinek, Diane F

AU - Witzig, Thomas Elmer

PY - 2001/2/1

Y1 - 2001/2/1

N2 - Purpose: Previous studies in patients with non-Hodgkin's lymphoma (NHL) and other malignancies have suggested that the presence of host infiltrates in the tumors of these patients may predict a better out-come. This study was undertaken to determine the prognostic importrance of the presence of T cells in the biopsy specimens of patients with B-cell NHL. Patients and Methods: Seventy-two patients with diffuse large B-cell NHL were prospectively evaluated at a single institution between 1987 and 1994. The percentage of CD3+, CD3+/HLA-DR+, CD4+, CD8+, and natural killer cells was determined by flow cytometry in the pretreatment diagnostic biopsy specimen and correlated with patient outcome. Results: An increase in the percentage CD4+ T cells in the pretreatment tumor biopsies significantly correlated with patient outcome. The percent of CD4+ T cells was also highly correlated with CD3+/HLA-DR+, CD45RO+, and low L-selectin (CD62L) expression, indicating that the CD4+ T, cells are activated memory T-helper cells. Those patients with increased numbers of CD4+ T cells, compared with other patients, had a significantly longer 5-year failure-free survival (72% v 43%, respectively; P = .04), as well as a significantly longer 5-year overall survival (65% v 38%, respectively; P = .05). When evaluated in a multivariate model, the International Prognostic Index and more than 20% infiltrating CD4+ T cells in the pretreatment biopsy were significant independent predictors of relapse-free and overall survival. Conclusion: The presence of increased numbers of activated CD4+ cells in the area of B-cell diffuse large-cell NHL predicts a better prognosis. This finding provides a strong rationale for the investigation of cellular immunotherapy in B-cell NHL.

AB - Purpose: Previous studies in patients with non-Hodgkin's lymphoma (NHL) and other malignancies have suggested that the presence of host infiltrates in the tumors of these patients may predict a better out-come. This study was undertaken to determine the prognostic importrance of the presence of T cells in the biopsy specimens of patients with B-cell NHL. Patients and Methods: Seventy-two patients with diffuse large B-cell NHL were prospectively evaluated at a single institution between 1987 and 1994. The percentage of CD3+, CD3+/HLA-DR+, CD4+, CD8+, and natural killer cells was determined by flow cytometry in the pretreatment diagnostic biopsy specimen and correlated with patient outcome. Results: An increase in the percentage CD4+ T cells in the pretreatment tumor biopsies significantly correlated with patient outcome. The percent of CD4+ T cells was also highly correlated with CD3+/HLA-DR+, CD45RO+, and low L-selectin (CD62L) expression, indicating that the CD4+ T, cells are activated memory T-helper cells. Those patients with increased numbers of CD4+ T cells, compared with other patients, had a significantly longer 5-year failure-free survival (72% v 43%, respectively; P = .04), as well as a significantly longer 5-year overall survival (65% v 38%, respectively; P = .05). When evaluated in a multivariate model, the International Prognostic Index and more than 20% infiltrating CD4+ T cells in the pretreatment biopsy were significant independent predictors of relapse-free and overall survival. Conclusion: The presence of increased numbers of activated CD4+ cells in the area of B-cell diffuse large-cell NHL predicts a better prognosis. This finding provides a strong rationale for the investigation of cellular immunotherapy in B-cell NHL.

UR - http://www.scopus.com/inward/record.url?scp=0035253726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035253726&partnerID=8YFLogxK

M3 - Article

C2 - 11157023

AN - SCOPUS:0035253726

VL - 19

SP - 720

EP - 726

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -